Pharmacokinetics of Human Plasma-Derived Antithrombin in Pediatric Patients Supported on Extracorporeal Membrane...

Area of Science:

• Pediatric Critical Care Medicine
• Pharmacokinetics
• Hematology

Background:

• Extracorporeal membrane oxygenation (ECMO) in critically ill children carries a high risk of thromboembolic events.
• Unfractionated heparin is standard anticoagulation, but acquired antithrombin (AT) deficiency can cause heparin resistance.
• AT activity monitoring and off-label AT replacement are common but lack optimal dosing guidelines.

Purpose of the Study:

• To characterize the pharmacokinetics (PK) of human plasma-derived AT in pediatric patients on ECMO.
• To develop evidence-based AT replacement regimens for different pediatric age groups undergoing ECMO.
• To establish optimal therapeutic drug monitoring strategies for AT in this population.

Main Methods:

• Retrospective cohort study of pediatric ECMO patients (0 to <18 years) at a single academic center.
• Utilized a two-compartment turnover model to describe AT pharmacokinetics.
• Analyzed PK parameters including clearance, volume of distribution, and basal AT input.

Main Results:

• A two-compartment model accurately described AT PK in pediatric ECMO patients.
• ECMO support was associated with a 50% reduction in bioavailable AT, doubling clearance and volume of distribution.
• PK parameter estimates under non-ECMO conditions were established.

Conclusions:

• Proposed age-specific AT replacement regimens for neonates and older children on ECMO to maintain target AT activity levels.
• Highlighted the importance of therapeutic drug monitoring for optimizing AT replacement therapy.
• Provided a foundation for improved anticoagulation management in pediatric ECMO.